Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended October 31, 2019; comparative periods ended October 31, 2018. Amounts are in U.S. dollars unless noted.
Business context and strategy
Champions Oncology provides oncology research and personalized-care services using its TumorGraft platform. Its Translational Oncology Solutions (TOS) business serves pharmaceutical and biotechnology customers; Personalized Oncology Solutions (POS) supports physicians. Management plans to expand TOS and says POS will not be a focus of future growth.
Financial performance and position
| Metric | Three months ended Oct. 31, 2019 | Six months ended Oct. 31, 2019 |
|---|---|---|
| Revenue | $7.625 million, up 13.9% | $14.362 million, up 11.2% |
| Gross margin | 49.1%, versus 48.4% | 46.9%, versus 49.4% |
| Operating income (loss) | $291,000, versus $275,000 | $(323,000), versus $757,000 income |
| Net income (loss) | $307,000, versus $267,000 | $(334,000), versus $750,000 income |
| Operating cash flow | $360,000 | $81,000, versus $400,000 |
Pharmacology services generated $7.358 million of quarterly revenue and $13.888 million for the six months. Management attributed revenue growth to more and larger studies, customer-base expansion, and enhanced study designs. Six-month operating costs rose 20.7% to $14.685 million, outpacing revenue growth; sales and marketing increased 46.7%, research and development 15.9%, and general and administrative expense 22.7%.
At October 31, cash was $2.784 million, total assets $13.947 million, total liabilities $11.833 million, and stockholders’ equity $2.114 million. The company reported a $1.2 million working-capital deficit and $71.0 million accumulated deficit. Operating lease liabilities totaled $3.906 million, including $477,000 current; the balance sheet also showed $2,000 current finance-lease liability. The filing reports no off-balance-sheet debt or similar obligations.
Six-month investing cash outflow was $522,000, mainly for laboratory equipment; financing cash outflow was $12,000. Cash declined $453,000 from April 30. The company adopted lease accounting effective May 1, 2019, recognizing operating lease assets and liabilities; comparative periods were not recast.
Changes, outlook, risks, and unusual items
- Quarterly revenue and net income increased year over year, while the six-month period shifted from operating and net income to losses, reflecting higher expenses relative to revenue.
- Management said six-month gross margin was pressured by costs for salaries, mice, and laboratory supplies incurred as study volume grew ahead of related revenue recognition.
- Management expects positive operating cash flow for fiscal 2020 and believes cash on hand and expected operating cash flows will fund operations for at least 12 months from the filing. It cautioned that additional capital, if needed, may not be available on acceptable terms.
- A $52,000 gain on disposal of laboratory equipment was recorded in other income. The company also reported $160,000 of purchase-price credit for equipment traded in.
- The company disclosed $151,000 of liabilities for uncertain tax positions related to a foreign operation, with no significant unrecognized tax benefits expected to be recorded in the next 12 months. No legal proceedings were reported.
- Related-party consulting payments to affiliates of board members totaled $65,250 for the six months; $15,311 was due to those parties at period end.
- Management identified estimates involving receivable collectability, revenue recognition, deferred-tax valuation allowances, goodwill, and share-based compensation as significant. The filing refers investors to risks in the company’s fiscal 2019 Form 10-K.
Important facts for investors to verify
- Whether revenue growth and study expansion can translate into improved six-month margins and sustained profitability.
- Cash conversion and working-capital trends, given the working-capital deficit and management’s reliance on expected positive operating cash flow.
- The timing of study-related costs versus revenue recognition, and the effect on gross margins.
- The scale and expected returns of TOS investment, alongside management’s reduced emphasis on POS.
- Lease commitments: disclosed future minimum operating-lease payments total $10.833 million.
- Potential dilution: 2.454 million options and 1.670 million warrants were outstanding; warrants expire at various dates through March 2020.